Shuchee Madhusudan, MD
Endocrinology, Diabetes & Metabolism · Kingston, NYNPI 1841477346
Payments from drug & device makers
Across 121 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$550
- Johnson & Johnson$305
- AbbVie$231
- Amgen$171
- Boehringer Ingelheim$165
- Merck$155
- plus $977 from 17 others
What the payments were for
- Speaking & faculty fees$502%
- Food & beverage$2,49298%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $550 |
| Johnson & Johnson | 16 | $305 |
| AbbVie | 9 | $231 |
| Amgen | 4 | $171 |
| Boehringer Ingelheim | 3 | $165 |
| Merck | 15 | $155 |
| GSK | 3 | $149 |
| Corcept Therapeutics | 7 | $144 |
| Shire North American Group Inc | 7 | $121 |
| Bayer | 1 | $100 |
| Sanofi-aventis U.S. LLC | 3 | $82 |
| Novo Nordisk | 4 | $60 |
| IBSA Pharma Inc. | 3 | $56 |
| Mylan Specialty L.p. | 3 | $49 |
| Lilly USA, LLC | 3 | $43 |
| Amarin Pharma, Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Insulet Corporation | 2 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Seqirus USA Inc | 1 | $17 |
| Electromed, Inc. | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,553 in reported general payments places this provider in the 60th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 510 | $437,834 |
| RybelsusSemaglutide | 308 | $370,740 |
| TrulicityDulaglutide | 236 | $304,718 |
| OzempicSemaglutide | 241 | $284,179 |
| MounjaroTirzepatide | 245 | $274,152 |
| FarxigaDapagliflozin Propanediol | 174 | $182,757 |
| TradjentaLinagliptin | 97 | $78,141 |
| JanuviaSitagliptin Phosphate | 81 | $65,860 |
| Tresiba Flextouch U-200Insulin Degludec | 61 | $54,708 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 59 | $45,767 |
| Teriparatide | 13 | $31,660 |
| ProliaDenosumab | 17 | $29,480 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 67 | $26,422 |
| FiaspInsulin Aspart (Niacinamide) | 17 | $21,954 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 88 | $18,480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic, Fiasp | $60 | $676,873566 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $43 | $587,507501 claims |
| Boehringer IngelheimJardiance, Tradjenta | $165 | $515,975607 claims |
| AstraZenecaFarxiga | $550 | $182,757174 claims |
| MerckJanuvia, Janumet | $155 | $83,159103 claims |
| AmgenProlia | $171 | $29,48017 claims |
| AbbVieSynthroid | $231 | $5,31662 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Kingston
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
- Robert SilverBrooklyn$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.